Table 2 Primary and secondary outcomes
Characteristic | No. (%) | Absolute difference, % (95%CI) | P | |
|---|---|---|---|---|
High-flow nasal cannula group (n = 158) | Conventional oxygen therapy group (n = 172) | |||
Primary outcome | Â | Â | Â | Â |
Criteria for intubation, No. (%) | 4 (2.5%) | 1 (0.6%) | 1.95 (− 0.8–4.7) | 0.198* |
Secondary outcome | Â | Â | Â | Â |
Treatment failure, No. (%) | 25 (15.8%) | 25 (14.5%) | 1.29 (− 6.5–9.0) | 0.745* |
Intubation, No. (%) | 3 (1.9%) | 1 (0.6%) | 1.95 (− 0.8–4.7) | 0.353* |
NPPV, No. (%) | 15 (9.5%) | 22 (12.8%) | − 3.3 (− 10.1–3.5) | 0.343* |
Duration of NPPV, median (IQR), days | 6.0 (2.0–10.0) | 5.5 (4.0–8.0) | 1.0 (− 2.7–4.7) | 0.780†|
Mortality in hospital, No. (%) | 0 (0%) | 1 (0.6%) |  |  > 0.999* |
Mortality at day 90, No. (%) | 5/153 (3.3%) | 5/171 (2.9%) | 0.34 (− 3.4–4.1) |  > 0.999* |
Length of hospital stay, median (IQR), days | 9.0 (7.0–13.0) | 8.0 (7.0–11.0) | 1.0 (0.0–2.0) | 0.021†|
Hospital cost, median (IQR), $ | 2298 (1613–3782) | 2005 (1439–2968) | 265 (− 104–632) | 0.006†|
Readmission rate at day 90, No. (%) | 25/153 (16.3%) | 23/170 (13.5%) | 2.8 (− 5.0–10.6) | 0.478* |